Before the advent of the anti-angiogenic VEGFR inhibitors, kidney cancer cure rates were on the order of 5%.
FORBES: How Do Oncologists Sort Through All the New Anticancer Drugs?
2.
After the drug was stopped, mice treated with the anti-angiogenic drug "had more metastases, the metastases occurred more quickly, and they died sooner, " Kerbel says.